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Introduction
Triple-negative breast cancer is characterised by absence of 
oestrogen receptor, progesterone receptor, and HER2 receptor 
amplification. Its pathogenesis is still not well understood, and 
it is associated with poor prognosis and high recurrence rate. 
Therefore, it is important to improve our understanding of the 
pathophysiology of triple-negative breast cancers in order that 
better therapeutic targets can be identified.1 Previous studies 
have reported the role of mitochondria-mediated metabolic 
reprogramming to fatty acid β-oxidation in triple-negative 
breast cancer.2 Mitochondria in the cancer cell respond to the 
change in nutrient status by sending signals in the form of 
metabolites, reactive oxygen species (ROS), or changes in 
adenosine diphosphate: adenosine triphosphate (ADP: ATP) 
ratio, which affects both nuclear gene expression and cytosolic 
signalling pathways.1,3 These mitochondria-mediated changes 
in nuclear gene expression help cancer cells survive and prolif-
erate. Trans-mitochondrial cybrids are an important tool to 
study the role of mitochondria in a defined nuclear back-
ground. Online portals such as the Gene Expression Omnibus 
(GEO) enable researchers to access multiple sets of gene 
expression data, which can be analysed and visualised using 
platforms such as cBioPortal for The Cancer Genome Atlas 
(TCGA) cancer genomics data.4,5 Integration of such analyses 
with laboratory-based studies represents a powerful approach 
to understand cancer biology phenotypes more deeply, provid-
ing greater opportunity for mechanistic insights in the system 
under study.
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ABSTRACT
BACkGRouND: Triple-negative breast cancer is an aggressive type of breast cancer with high risk of recurrence. It is still poorly under-
stood and lacks any targeted therapy, which makes it difficult to treat. Thus, it is important to understand the underlying mechanisms and 
pathways that are dysregulated in triple-negative breast cancer.
METHoDS: To investigate the role of mitochondria in triple-negative breast cancer progression, we analysed previously reported gene 
expression data from triple-negative breast cancer cybrids with SUM-159 as the nuclear donor cell and SUM-159 or A1N4 (c-SUM-159, 
c-A1N4) as the mitochondrial donor cells and with 143B as the nuclear donor cell and MCF-10A or MDA-MB-231 (c-MCF-10A, c-MDA-
MB-231) as the mitochondrial donor cells. The role of potential biomarkers in cell proliferation and migration was examined in SUM-159 and 
MDA-MB-231 cells using sulforhodamine B and wound healing assays.
RESulTS: Rank product analysis of cybrid gene expression data identified 149 genes which were significantly up-regulated in the cybrids 
with mitochondria from the cancer cell line. Analysis of previously reported breast tumour gene expression datasets confirmed 9 of the 149 
genes were amplified, up-regulated, or down-regulated in more than 10% of the patients. The genes included NDRG1, PVT1, and EXT1, 
which are co-located in cytoband 8q24, which is frequently amplified in breast cancer. NDRG1 showed the largest down-regulation in the 
cybrids with benign mitochondria and was associated with poor prognosis in a breast cancer clinical dataset. Knockdown of NDRG1 expres-
sion significantly decreased proliferation of SUM-159 triple-negative breast cancer cells.
CoNCluSioNS: These results indicate that mitochondria-regulated nuclear gene expression helps breast cancer cells survive and prolif-
erate, consistent with previous work focusing on an Src gene signature which is mitochondria regulated and drives malignancy in breast 
cancer cybrids. This is the first study to show that mitochondria in triple-negative breast cancer mediate significant up-regulation of a num-
ber of genes, and silencing of NDRG1 leads to significant reduction in proliferation.
kEywoRDS: NDRG1, breast cancer, cybrids
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This study considered changes in nuclear gene expression 
when benign mitochondria are introduced into a metastatic 
nuclear background, using microarray data2,6 from triple-nega-
tive breast cancer cybrids to identify potential novel targets. 
Publicly available gene expression datasets of breast tumours 
were used to prioritise potential candidates, which were vali-
dated using short interfering RNA (siRNA)-mediated silenc-
ing to demonstrate the effectiveness of the approach. Among 9 
genes which were significantly down-regulated, NDRG1 was 
most affected and was also confirmed to be amplified and up-




The human triple-negative breast cancer cell lines MDA-MB- 
231 and SUM-159, purchased from American Type Culture 
Collection (ATCC) were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM; Sigma-Aldrich, USA) supple-
mented with 10% foetal calf serum (FCS), 50 U mL−1 penicillin, 
and 50 mg mL−1 streptomycin (all Sigma-Aldrich, USA). Cells 
were maintained at 5% CO2 at 37°C in a humidified incubator. 
Reagents and antibodies
Phosphatase inhibitor cocktail 2, phosphatase inhibitor cock-
tail 3, cOmplete protease inhibitor cocktail, and aprotinin were 
obtained from Sigma-Aldrich. NDRG1 siRNA was 




ON-TARGETplus non-targeting siRNA (D-001810-01-05) 
and DharmaFECT 4 transfection reagent (T-2004-02) were 
from Horizon Discovery. Anti-NDRG1 (D8G9) XP rabbit 
antibody (9485S) and pre-stained protein markers (13953S) 
were obtained from Cell Signalling Technology.
Short interfering RNA transfection
The MDA-MB-231 cells and SUM-159 cells were seeded at a 
density of 3.00 × 105 and 2.75 × 105 cells, respectively, in a 
6-well tissue culture plate. After 24 hours, cells were transfected 
with 25 nM of NDRG1-targeting siRNA or non-targeting 
siRNA using DharmaFECT 4. Culture medium was changed 
to DMEM + 10% FCS + AB medium 24 hours after treat-
ment. Cells were lysed at 48, 72, 96, and 120 hours after siRNA 
treatment.
Cell lysis
Tissue culture plates were washed with phosphate-buffered 
saline (PBS) and treated with lysis buffer (50 mM Tris-HCl, 
pH 7.5, 5 mM EGTA, pH 8.5, and 150 mM NaCl) containing 
1% Triton X-100, 100 μL phosphatase inhibitor cocktail 2, 
100 μL phosphatase inhibitor cocktail 3, 50 μL aprotinin and 
1× cOmplete protease inhibitor cocktail. Lysates were clarified 
by centrifugation at 13 000 × g for 5 minutes. All procedures 
were performed at 4°C. Protein concentration was determined 
using a bicinchoninic acid (BCA) assay, and cell lysates were 
stored at –80°C.
Western blot analysis
Samples containing 40 μg of protein were resolved by sodium 
dodecyl sulphate–polyacrylamide gel electrophoresis. Resolved 
proteins were transferred to polyvinylidene fluoride membrane, 
which was then blocked using a 50:50 solution of PBS and 
Odyssey Blocking Buffer (LI-COR Biosciences, USA). The 
membrane was then incubated with anti-NDRG1 antibody 
(1:1000) overnight at 4°C. The membrane was washed and 
incubated with secondary antibody (1:10 000) and imaged 
using an Odyssey infrared imager (LI-COR Biosciences, 
USA). Anti-α-tubulin antibody (Abcam) diluted 1:8000 was 
used as a loading control.
Immunocytochemistry
The MDA-MB-231 and SUM-159 cells were transfected 
with NDRG1-targeting siRNA. Cells were washed with PBS 
and fixed in acetone for 10 minutes at 4°C. Fixed cells were 
washed twice in PBS containing 0.1% Tween 20 (PBS-T) 
and placed in H2O2 solution for 10 minutes. Cells were 
washed twice with PBS-T and placed in DAKO blocking 
solution for 10 minutes at room temperature. Primary anti-
body diluted 1:800 as recommended in DAKO antibody dilu-
tion solution was added for 1 hour at room temperature. Cells 
were washed with PBS-T and incubated with appropriate 
secondary antibody (Envision labelled polymer) for 30 min-
utes at room temperature. Cells were treated with DAB solu-
tion for 10 minutes, followed by washing and counterstaining 
with haematoxylin for 40 seconds. After repeated cycle of 
washes with alcohol and xylene, cells were dried and observed 
by light microscopy.
Cell proliferation assay
Cells were seeded in triplicate in 96-well plates (800 cells per 
well). Cells were treated with 25 nM NDRG1 siRNA after 
24 hours. Following siRNA treatment, cells were fixed at 48, 
72, 96, and 120 hours using 50 µL 25% trichloroacetic acid for 
1 hour at 4°C. Plates were washed with water and left to dry. 
Next, 50 µL sulforhodamine B (SRB) dye were added, and 
plates were incubated for 30 minutes at room temperature. 
Plates were washed with 1% glacial acetic acid solution and left 
for drying. Once dry, 150 µL Tris buffer was added, and after 
1 hour, plates were read at optical density 540 nm using a 
BP800 Microplate Reader (BIOHIT Healthcare, Finland).
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Wound healing (scratch) assay
The SUM-159 and MDA-MB-231 cells were seeded at 
275 000 and 300 000 cells per well, respectively, in a 6-well tis-
sue culture plate. The cells were treated with NDRG1 siRNA 
after 24 hours, and cell culture medium was changed 24 hours 
post-transfection. A scratch was made using a 200-µL pipette 
tip at 48 and 72 hours post-transfection for SUM-159 and 
MDA-MB-231 cells, respectively. Photomicrographs were 
taken using a light microscope at 0, 6, and 24 hours using a 
2.5× objective.
Acquisition of gene expression data
Gene expression data of transmitochondrial cybrids, with mod-
erately metastatic triple-negative breast cancer cells SUM-159 
as the common nuclear background, and mitochondria from 
benign breast epithelium (A1N4) or moderately metastatic tri-
ple-negative breast cancer cells (SUM-159), were downloaded 
from the NCBI GEO repository (GSE72319).2 Another data-
set of transmitochondrial cybrid data, with metastatic osteosar-
coma-derived 143B ells as the common nuclear background, 
and mitochondria from noncancerous mammary epithelial 
MCF-10A cells or breast cancer MDA-MB-468 cells, was 
gratefully obtained on request from Benny Kaipparettu (Baylor 
College of Medicine, Houston, Texas, USA).6
Data processing and analysis
Bioconductor7 packages from the R programming language8 
were used for analysis. A custom chip definition file (CDF) 
from brainarray9 was used to map Affymetrix probe level data 
to Entrez gene ID, and robust multi-array averaging imple-
mented by the affy package was used for normalisation. The 
dataset was filtered using mas5calls implemented in the affy 
package to remove genes which were absent in more than 4 
samples (out of a total of 6 samples). The Rank Products 
method10 of analysis was implemented by the rankprod package 
to identify differentially expressed genes. Pathway analysis was 
performed using the SPIA package (R/Bioconductor). Gprofiler 
was used to perform gene ontology enrichment analysis. cBio-
Portal (www.cbioportal.org/) was used to examine the genes in 
publicly available breast tumour datasets. Survival analysis was 
performed with the survivALL package.11
Results
Cybrid-specif ic gene expression is associated with 
cell proliferation, blood vessel morphogenesis, 
response to hypoxia, and focal adhesions
To identify genes whose expression is regulated by mitochon-
dria derived from normal and malignant breast cancer cell line 
against the background of malignant breast cancer cell line, we 
compared gene expression data derived from the cancer and 
normal cybrids (c-A1N4 vs c-SUM-159 and c-MCF-10A vs 
c-MDA-MB-231). Rank Product analysis identified 2851 and 
2682 genes (P < .05) differentially expressed in the respective 
datasets, with similar proportions up- and down-regulated. A 
total of 622 genes were differentially expressed across the data-
sets, of which 149 genes were up-regulated and 183 genes were 
down-regulated in cybrids with mitochondria from cancer cells 
compared with cybrids from benign cells (Figure 1A). Gprofiler 
was used to examine the over-representation of gene ontology 
terms for the 149 genes up-regulated in both SUM-159 and 
143B triple-negative breast cancer cybrid models. These were 
found to be enriched in biological processes such as cell prolif-
eration, blood vessel morphogenesis, and response to hypoxia 
(Figure 1B). Signalling pathway impact analysis identified 7 
pathways enriched among up-regulated genes, including 
ECM-receptor interaction, focal adhesion, and small cell lung 
cancer pathways (Figure 1C).
Cybrid-specif ic genes are differentially expressed in 
triple-negative breast tumours
To investigate the relevance of the expression of the cybrid-
associated genes, we examined gene expression and copy num-
ber variation in publicly available gene expression datasets. Out 
of the 149 genes, 9 were observed to be amplified, up-regulated, 
or down-regulated in more than 10% of the 963 patients in the 
TCGA breast cancer dataset.12 Of these, 3 genes, NDRG1, 
EXT1, and PVT1, are known to be located in the frequently 
amplified 8q24 cytoband in breast cancer (Figure 2A). NDRG1 
had the greatest fold change in cybrids and was also observed 
to be amplified and overexpressed in a substantial proportion of 
breast cancer patient samples. NDRG1 was up-regulated in 
cybrids with cancer cell–derived mitochondria (2.7-fold change 
in c-SUM-159 vs c-A1N4).13 Comparing NDRG1 gene 
expression across breast cancer subtypes, it was observed that 
median expression of NDRG1 was much greater in the basal 
triple-negative subtype (Figure 2B and C) in both the TCGA 
and METABRIC13 datasets (Figure 2B and C).
Silencing of NDRG1 reduces proliferation, but does 
not affect migration of breast cancer cells
Comprehensive survival analysis of NDRG1 in the TCGA 
RNAseq dataset12 that assessed all possible cut-points using 
the survivALL R package11 revealed that 25% (131 of 525) of 
cut-points were significant (P < .05), which is consistent with 
previous studies of microarray data showing that NDRG1 
expression is positively correlated with invasiveness in breast 
cancer (Figure 3) and implicated in lipid metabolism.14,15 To 
explore the effect of NDRG1 in the basal subtype of breast 
cancer, siRNA targeting NDRG1 and non-targeting siRNA as 
a negative control were used for transfecting SUM-159 and 
MDA-MB-231 cells, as well as a mock transfection control 
(transfection reagent only). Cell lysates were collected at 48, 72, 
96, and 120 hours post-transfection. Western blot analysis 
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revealed that maximum NDRG1 knockdown for SUM-159 
cells (84% knockdown) was obtained 48 hours after transfec-
tion and that, for MDA-MB-231 cells (89% knockdown), this 
was at 72 hours post-transfection using 25 nM siRNA (Figure 
4A). Immunocytochemistry further confirmed the efficiency of 
NDRG1 siRNA transfection compared with the non-targeting 
siRNA negative control and mock transfection control (Figure 
4B). Absence of brown colouration in siRNA-transfected cells 
confirmed siRNA-mediated knockdown of NDRG1 in 
MDA-MB-231 and SUM-159 cells. Proliferation of NDRG1 
siRNA-treated, non-targeting siRNA-treated, mock-trans-
fected, and untreated cells was examined by SRB assay at 48, 
Figure 1. Analysis of cybrid-specific gene expression in triple-negative breast cancer cells. (A) Venn diagrams showing the 183 genes down-regulated 
and 149 genes up-regulated in both SUM-159 and 143B triple-negative breast cancer cybrid models. (B) Gene ontology enrichment analysis of the 149 
genes significantly up-regulated in both triple-negative breast cancer cybrid models. (C) Signalling pathway impact analysis showing 3 significantly 
inhibited pathways (false discovery rate, FDR < 0.1).
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72, 96, and 120 hours post-transfection. Optical density values 
obtained in triplicate at 540 nm were averaged and normalised 
to day 0 control and untreated control samples at each time 
point. In SUM-159 cells, a significant reduction in cell prolif-
eration was observed at 120 hours post-transfection (1-way 
analysis of variance, P = .03) (Figure 4C). The MDA-MB-231 
cells also showed a decrease in proliferation 72 hours post-
transfection, but it was not statistically significant (Figure 4C). 
To assess the impact of NDRG1 silencing on the migration of 
SUM-159 and MDA-MB-231 cells, wound healing assays 
were performed 48 and 72 hours post-transfection, respectively. 
Compared with non-targeting siRNA, NDRG1 siRNA-
treated cells did not exhibit any significant changes to cell 
migration (Figure 4D).
Discussion
Mitochondria in cancer cells respond to changes in environ-
mental cues by switching between metabolic pathways to help 
Figure 2. Cybrid-specific potential targets are differentially expressed in breast tumours. (A) Dysregulated genes in more than 10% of the patients in the 
TCGA breast cancer dataset,12 of which 3 genes, NDRG1, EXT1, and PVT1, located in the frequently amplified 8q24 cytoband. (B) NDRG1 was also 
amplified or overexpressed in 30% of the METABRIC dataset.13 (C) The highest levels of NDRG1 expression are observed in the basal subtype in both 
datasets. TCGA indicates The Cancer Genome Atlas.
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cancer cells survive and proliferate,2 but mitochondria-medi-
ated changes in nuclear gene expression are not well studied. It 
is therefore important to investigate genes whose expression is 
regulated by mitochondria and how important these are for 
proliferation of cancer cells. To explore the potential impact of 
mitochondria on nuclear gene expression, we analysed gene 
expression data from the cybrid model of triple-negative breast 
cancer cell lines. Gene expression data from multiple cell line 
studies and a large patient cohort enabled identification of 
potential candidate biomarkers (NDRG1, EXT1, PVT1, F11R, 
SOX13, ANKRD13B, SCPEP1, NR1D1, CPT1A). NDRG1 
was observed to be amplified and up-regulated in a large pro-
portion of the basal subtype of triple-negative breast cancer 
among invasive breast carcinoma patients. NDRG1 has been 
mostly shown to have a protective function in cancer, although 
some research suggests that its expression is positively corre-
lated with invasiveness in breast cancer, and it plays an impor-
tant role in low-density lipoprotein receptor recycling in A431 
squamous carcinoma cells.14,15 In addition, mutations in 
NDRG1 are the cause of Charcot-Marie-Tooth disease type 
4D, which is a demyelinating form of Charcot-Marie-Tooth 
disease that affects the peripheral nervous system.16 These 
studies suggest a possible association of NDRG1 with lipid 
trafficking and growth in the basal subtype of breast cancer.
Previous work by Park et al and Kaipparettu et al focussed 
on Src gene signature which is mitochondria regulated and 
drives malignancy in breast cancer cybrids. However, this is the 
first time that NDRG1 silencing has been shown to affect the 
proliferation of triple-negative breast cancer cells, although it 
had no effect on cell migration. These results call for a detailed 
analysis of the molecular mechanism by which mitochondria in 
metastatic breast cells cause up-regulation of NDRG1 expres-
sion and how NDRG1 regulates the proliferation of SUM-159 
cells. One probable explanation for the significant decrease in 
proliferation in cybrids with benign mitochondria against a 
metastatic cell nuclear background could be that, in metastatic 
breast cancer cells, mitochondria-mediated up-regulation of 
NDRG1 expression enhances lipid uptake by SUM-159 cells, 
which may promote cell proliferation in these lipid-dependent 
cell lines. When a cybrid model is prepared with this metastatic 
cell line as nuclear background and a benign cell line as mito-
chondrial donor, NDRG1 expression is significantly down-
regulated, which results in reduced cell proliferation. In 
contrast, NDRG1 silencing did not have any significant impact 
on proliferation and migration of MDA-MB-231 cells. The 
reduction in proliferation of SUM-159 cells was observed 
120 hours post-transfection. At this time point, knockdown of 
NDRG1 expression in SUM-159 cells (73% knockdown) was 
more complete than in MDA-MB-231 cells (58% knock-
down). Therefore, more stable silencing of NDRG1 in 
MDA-MB-231 cells may enable better evaluation of its impact 
on proliferation. In a previous study, silencing NDRG1 was 
found to reduce cell proliferation rates, causing lipid metabo-
lism dysfunction including increased fatty acid incorporation 
into neutral lipids and lipid droplets. Analysis of public gene 
expression data also suggests that EXT1 and PVT1 may be 
promising gene targets. These are all present in cytoband 8q24, 
which is frequently amplified in breast cancer and also in the 
SUM-159 cell line.17 Thus, it would be interesting to evaluate 
how these genes together affect prognosis in triple-negative 
breast cancer. We acknowledge the limited nature of this study, 
but feel that it provides useful supportive data for understand-
ing the role of NDRG1 in breast cancer. In future, it would be 
of interest to study NDRG1 in the context of other subtypes 
beyond triple-negative breast cancers.
Conclusions
This study demonstrates the use of gene expression data to study 
the impact of mitochondria in proliferation and migration of 
triple-negative breast cancer cells. Analysis of triple-negative cell 
lines and cybrids identified potential mitochondria-regulated 
gene candidates that were evaluated in clinical datasets. NDRG1 
was found to be the most up-regulated gene in cybrids with cancer 
cell–derived mitochondria, and it is amplified and up-regulated in 
Figure 3. Elevated NDRG1 expression is associated with poor prognosis 
in patients with breast cancer. (A) Comprehensive survival analysis using 
survivALL demonstrates that high levels of NDRG1 expression are 
associated with poor outcome in the TCGA dataset. Over 25% of all 
possible cut-points are significant (P < .05), highlighted in shades of blue, 
lower = darker. (B) Kaplan-Meier plot showing the most significant 
cut-point where high NDRG1 expression is associated with worse 
outcome. TCGA indicates The Cancer Genome Atlas.
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a large fraction of patients with the basal subtype of invasive 
breast carcinoma.17 Silencing NDRG1 significantly reduced pro-
liferation, but has no effect on migration, of SUM-159 cells. 
Further investigations on how NDRG1 affects low-density lipo-
protein uptake in triple-negative breast cancer may provide new 
therapeutic insights in the treatment of breast cancer.
Figure 4. Silencing NDRG1 in SUM-159 and MDA-MB-231 cells. (A) Western blot analysis of lysates from MDA-MB-231 and SUM-159 cell lines 
transfected with NDRG1 siRNA at 48, 72, 96, and 120 hours post-transfection. (B) Transfection after 48 hours was validated by immunocytochemistry for 
depleted NDRG1 protein (brown) in MDA-MB-231 and SUM-159 cells. Blank control represents non-transfected control cells; transfection reagent 
represents cells in the presence of DharmaFECT 4 transfection reagent only; negative control represents cells transfected with non-targeting control 
siRNA. (C) Proliferation of SUM-159 (top) and MDA-MB-231 (bottom) cells was determined using the SRB assay at 120 and 72 hours, respectively, 
post-transfection with NDRG1 siRNA or non-targeting control siRNA. Experiments were performed in triplicate, and data were normalised to control 
(untreated) cells; statistical significance was computed using 1-way ANOVA. (D) Migration rate of SUM-159 (top) and MDA-MB-231 (bottom) cells was 
determined by wound healing assay 48 hours after transfection. Relative migration was determined after 24 hours. Data were normalised to control cells; 
statistical significance was computed using 1-way ANOVA. ANOVA indicates analysis of variance; SRB, sulforhodamine B.
8 Breast Cancer: Basic and Clinical Research 
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